Pure Biologics establishes Doto Medical special purpose vehicle

Pure Biologics establishes the Doto Medical special purpose vehicle and signs an agreement with the renowned international business advisor Clairfield Partners to accelerate the commercialization of the PB103 aptamer project.

News

Inquiries

“How Science Becomes Business” – Pure Biologics e-conference for investors

26 November

2021

“How Science Becomes Business” – Pure Biologics e-conference for investors

Find out more about the science behind our ideas and how we turn it into value.

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

3 November

2021

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

A new partner on the map of the innovation ecosystem (🇵🇱)

Pure Biologics at the Writing the Future of Drug Discovery and Development

8 October

2021

Pure Biologics at the Writing the Future of Drug Discovery and Development

Pure Biologics was invited to the event: "Writing the Future of Drug Discovery and Development", where it will present the first results of partnering with Twist Bioscience Corporation.

PB001 – completion of the first pilot preclinical study

30 August

2021

PB001 – completion of the first pilot preclinical study

Completion of the first preclinical pilot study in project PB001, in which Pure Biologics is developing a novel immunotherapy for the treatment of colorectal cancer.

Dr. Pieter Spee is the new Chief Scientific Officer

1 June

2021

Dr. Pieter Spee is the new Chief Scientific Officer

Dr. Pieter Spee, a medical biologist and manager with many years of experience in international biopharmaceutical companies, was appointed to the position of Chief Scientific Officer, CSO.

9 October

2020

Pure Biologics establishes Doto Medical special purpose vehicle

“How Science Becomes Business” – Pure Biologics e-conference for investors

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

Pure Biologics at the Writing the Future of Drug Discovery and Development

PB001 – completion of the first pilot preclinical study

Dr. Pieter Spee is the new Chief Scientific Officer

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/1/20 21.01.2020